Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaPharmacokinetics and tissue disposition of lenalidomide in mice.Multiple myeloma in the marrow: pathogenesis and treatments.The potential role of Aurora kinase inhibitors in haematological malignancies.Kinase inhibitors as potential agents in the treatment of multiple myeloma.ENMD-2076 for hematological malignancies.JAK2 inhibition for the treatment of hematologic and solid malignancies.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Multi-kinase inhibitors, AURKs and cancer.Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.Activity of BKM120 and BEZ235 against Lymphoma Cells.The Effect of Aurora Kinase Inhibitor on Adhesion and Migration in Human Breast Cancer Cells and Clinical Implications.The therapeutic potential of cell cycle targeting in multiple myeloma.Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.Loss of FAM46C Promotes Cell Survival in Myeloma.Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
P2860
Q26775723-29282E38-1637-406E-AB7E-DEF6D9475C63Q33983255-B5CD9A58-86D7-4BCF-9699-AF31E9C08617Q34194704-BBBAA2D3-8C44-4C63-803F-B4E219A07094Q35915726-5C015AB2-74FE-4DA5-82E3-A51EFF90BB9CQ36331493-E8B84586-0205-48EF-8826-28E5EB3E2FCDQ36725401-C599EBC2-94D5-4002-A517-E2AB90AB1AFDQ37167047-E50D785F-4683-4E86-831E-3EBB015E1899Q37697253-18B2B7BF-1365-4790-94AB-BD54DD2BAA3FQ37991379-AE4C190A-4479-4707-A588-DE220F165DC7Q38001733-0E650DF4-95BC-4030-9F71-81ED3AEB4608Q38164139-D54102FF-8DD1-44CA-9FD2-968424781693Q38796360-0E9B5A8E-FFEB-47FF-858D-0FAB32E87454Q38872009-F9862DE8-0FF2-4B15-B23B-0F71FE598473Q38894287-9760417B-8824-41B2-98FF-7D779ED74BC0Q39429784-BA2E1598-B893-40A6-BADE-9820699810EAQ40565806-5D00612C-7895-472C-82CA-F0A3ADFCC5ADQ41855451-42747909-2C4C-4AD0-B4BC-EF19C361402EQ46364752-9A9EEA25-E405-4E67-A3ED-E04C6E5FD041Q47203904-896A0157-98FC-49E1-9B4D-B184055167BAQ48922287-4F84E9DA-3AAF-4113-B6A7-60155E0D12F1Q50942246-3B6E1DDD-5B12-4172-BDFA-18A933E58F9CQ53784890-A1490B9B-9A79-4F53-942E-12CC36912E58Q53817434-26CC0F4F-0139-4991-9668-4F0C7BAAC759Q54120110-15B73888-55EA-43E4-B2AB-E0EFDF0A948DQ57818334-DB645F42-C780-430A-AF1E-C2C06E153A6D
P2860
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antimyeloma activity of a mult ...... combination with lenalidomide.
@en
Antimyeloma activity of a mult ...... combination with lenalidomide.
@nl
type
label
Antimyeloma activity of a mult ...... combination with lenalidomide.
@en
Antimyeloma activity of a mult ...... combination with lenalidomide.
@nl
prefLabel
Antimyeloma activity of a mult ...... combination with lenalidomide.
@en
Antimyeloma activity of a mult ...... combination with lenalidomide.
@nl
P2093
P2860
P1476
Antimyeloma activity of a mult ...... combination with lenalidomide.
@en
P2093
Anuj Mahindra
Christine Unitt
Dharminder Chauhan
Diana Cirstea
Erik A Nelson
Gullu Gorgun
Kishan Patel
Loredana Santo
Madhavi Bandi
Matt Squires
P2860
P304
P356
10.1158/1078-0432.CCR-10-3012
P407
P577
2011-03-23T00:00:00Z